<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
(RULE 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13D-11(b)(c), AND (d) AND AMENDMENTS THERETO
FILED
PURSUANT TO RULE 13d-2(b)
(AMENDMENT NO. 4)*
LIGAND PHARMACEUTICALS INCORPORATED
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock
- --------------------------------------------------------------------------------
(Title of Class of Securities)
53220K 10 8
- --------------------------------------------------------------------------------
(CUSIP Number)
12/31/98
- --------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[X] Rule 13d-1(d)
- -----------------
1. The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
Page 1 of 7 pages
<PAGE> 2
- ---------------------------
13G
CUSIP NO. 53220K 10 8
- ---------------------------
- --------- ----------------------------------------------------------------------
1 Name of Reporting Persons
S.S. or I.R.S. Identification Nos. of Above Persons
ALLERGAN, INC.
- --------- ----------------------------------------------------------------------
2 Check the Appropriate Box if a Member of a Group* (a) [ ]
(b) |X|
- --------- ----------------------------------------------------------------------
3 SEC Use Only
- --------- ----------------------------------------------------------------------
4 Citizenship or Place of Organization
DELAWARE
- --------- ----------------------------------------------------------------------
5
Sole Voting Power
Number of 2,245,944
------ -----------------------------------------------
Shares 6 Shared Voting Power
Beneficially Owned by
Each Reporting Person 0
with ------ -----------------------------------------------
7 Sole Dispositive Power
2,245,944
------ -----------------------------------------------
8 Shared Dispositive Power
0
- --------- ----------------------------------------------------------------------
9 Aggregate Amount Beneficially Owned by each Reporting Person
2,245,944
- --------- ----------------------------------------------------------------------
10 Check Box if the Aggregate Amount in Row (9) excludes certain shares*
- --------- ----------------------------------------------------------------------
11 Percent of Class represented by amount in Row 9
5.3%
- --------- ----------------------------------------------------------------------
12 Type of Reporting Person*
CO
- --------- ----------------------------------------------------------------------
Page 2 of 7 pages
<PAGE> 3
- ---------------------------
13G
CUSIP NO. 53220K 10 8
- ---------------------------
- --------- ----------------------------------------------------------------------
1 Name of Reporting Persons
S.S. or I.R.S. Identification Nos. of Above Persons
ALLERGAN PHARMACEUTICALS (IRELAND) LTD., INC.
- --------- ----------------------------------------------------------------------
2 Check the Appropriate Box if a Member of a Group* (a) [ ]
(b) |X|
- --------- ----------------------------------------------------------------------
3 SEC Use Only
- --------- ----------------------------------------------------------------------
4 Citizenship or Place of Organization
PANAMA
- --------- ----------------------------------------------------------------------
5
Sole Voting Power
Number of 2,245,944
------ -----------------------------------------------
Shares 6 Shared Voting Power
Beneficially Owned by
Each Reporting Person 0
with ------ -----------------------------------------------
7 Sole Dispositive Power
2,245,944
------ -----------------------------------------------
8 Shared Dispositive Power
0
- --------- ----------------------------------------------------------------------
9 Aggregate Amount Beneficially Owned by each Reporting Person
2,245,944
- --------- ----------------------------------------------------------------------
10 Check Box if the Aggregate Amount in Row (9) excludes certain shares*
- --------- ----------------------------------------------------------------------
11 Percent of Class represented by amount in Row 9
5.3%
- --------- ----------------------------------------------------------------------
12 Type of Reporting Person*
CO
- --------- ----------------------------------------------------------------------
Page 3 of 7 pages
<PAGE> 4
- ---------------------------
13G
CUSIP NO. 53220K 10 8
- ---------------------------
- --------- ----------------------------------------------------------------------
1 Name of Reporting Persons
S.S. or I.R.S. Identification Nos. of Above Persons
ALLERGAN HOLDINGS, INC.
- --------- ----------------------------------------------------------------------
2 Check the Appropriate Box if a Member of a Group* (a) [ ]
(b) |X|
- --------- ----------------------------------------------------------------------
3 SEC Use Only
- --------- ----------------------------------------------------------------------
4 Citizenship or Place of Organization
DELAWARE
- --------- ----------------------------------------------------------------------
5
Sole Voting Power
Number of 2,245,944
------ -----------------------------------------------
Shares 6 Shared Voting Power
Beneficially Owned by
Each Reporting Person 0
with ------ -----------------------------------------------
7 Sole Dispositive Power
2,245,944
------ -----------------------------------------------
8 Shared Dispositive Power
0
- --------- ----------------------------------------------------------------------
9 Aggregate Amount Beneficially Owned by each Reporting Person
2,245,944
- --------- ----------------------------------------------------------------------
10 Check Box if the Aggregate Amount in Row (9) excludes certain shares*
- --------- ----------------------------------------------------------------------
11 Percent of Class represented by amount in Row 9
5.3%
- --------- ----------------------------------------------------------------------
12 Type of Reporting Person*
CO
- --------- ----------------------------------------------------------------------
Page 4 of 7 pages
<PAGE> 5
ITEM 1.
(a) Name of Issuer: Ligand Pharmaceuticals Incorporated ("Issuer")
(b) Address of Issuer's Principal Executive Offices:
10275 Science Center Drive
San Diego, CA 92121
ITEM 2.
(a) Name of Person Filing: Allergan, Inc.
Allergan Pharmaceuticals (Ireland) Ltd., Inc.
Allergan Holdings, Inc.
(b) Address of Principal Business Office or, if none, Residence:
2525 Dupont Drive
Irvine, CA 92612
(c) Place of Organization: Allergan, Inc. - Delaware
Allergan Pharmaceuticals (Ireland) Ltd., Inc. - Panama
Allergan Holdings, Inc. - Delaware
(d) Title of Class of Securities: Common Stock
(e) CUSIP Number: 53220K 10 8
ITEM 3. NOT APPLICABLE.
ITEM 4. OWNERSHIP.
(a) Amount Beneficially Owned: Each corporation beneficially owned
2,245,944 shares of Common Stock as of December 31, 1998.
(b) Percent of Class: 5.3%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 2,245,944
(ii) shares power to vote or to direct the vote: 0
(iii) sole power to dispose or to direct the disposition of:
2,245,944
(iv) shared power to dispose or to direct the disposition of: 0
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
If this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the beneficial owner of more
than five percent of the class of securities, check the following: |X|
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Not applicable
Page 5 of 7 pages
<PAGE> 6
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH
ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING
COMPANY.
Not applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
Not applicable.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
Not applicable.
ITEM 10. CERTIFICATION
Not applicable.
Page 6 of 7 pages
<PAGE> 7
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
February 5, 1999
Date
ALLERGAN, INC.
By: /s/ Douglas S. Ingram
-------------------------------------------
Signature
Douglas S. Ingram, Assistant Secretary
-------------------------------------------
Name/Title
ALLERGAN PHARMACEUTICALS (IRELAND) LTD.,
INC.
By: /s/ Francis R. Tunney, Jr.
-------------------------------------------
Signature
Francis R. Tunney, Jr., Secretary
-------------------------------------------
Name/Title
ALLERGAN HOLDINGS, INC.
By: /s/ Jeffrey L. Edwards
-------------------------------------------
Signature
Jeffrey L. Edwards, Treasurer
-------------------------------------------
Name/Title
Page 7 of 7 pages
